Digital gait biomarkers in Parkinson’s disease: susceptibility/risk, progression, response to exercise, and prognosis.

Publication date: Mar 21, 2025

This narrative review examines the utility of gait digital biomarkers in Parkinson’s disease (PD) research and clinical trials across four contexts: disease susceptibility/risk, disease progression, response to exercise, and fall prediction. The review of the literature to date suggests that upper body characteristics of gait (e. g., arm swing, trunk motion) may indicate susceptibility/risk of PD, while pace aspects (e. g., gait speed, stride length) are informative for tracking disease progression, exercise response, and fall likelihood. Dynamic stability aspects (e. g., trunk regularity, double-support time) worsen with disease progression but can improve with exercise. Gait variability emerges as a sensitive biomarker across all 4 contexts but with low specificity. The lack of standardized gait testing protocols and the lack of a minimum set of quantified digital gait biomarkers limit data harmonization across studies. Future studies, using a commonly agreed upon protocol, could be used to demonstrate the utility of specific gait biomarkers for clinical practice.

Open Access PDF

Concepts Keywords
Biomarker Biomarkers
Future Clinical
Informative Contexts
Parkinsons Digital
Swing Exercise
Fall
Gait
Parkinson
Pd
Progression
Risk
Susceptibility
Utility

Semantics

Type Source Name
disease MESH gait
disease MESH Parkinson’s disease
disease MESH disease progression
disease MESH Mobility limitations
disease MESH functional independence
drug DRUGBANK Gold
drug DRUGBANK Ilex paraguariensis leaf
drug DRUGBANK Tropicamide
disease MESH movement disorders
drug DRUGBANK Levodopa
disease MESH tremor
drug DRUGBANK Trihexyphenidyl
drug DRUGBANK Profenamine
drug DRUGBANK Dopamine
disease MESH REM behavior disorder
disease MESH synucleinopathies
disease MESH Lewy body dementia
disease MESH abnormalities
drug DRUGBANK Coenzyme M
disease MESH etiology
disease MESH Cognitive Impairment
disease MESH Parkinsonism
drug DRUGBANK Tretamine
drug DRUGBANK Isoxaflutole
drug DRUGBANK Trestolone
disease MESH progressive supranuclear palsy
disease MESH corticobasal syndrome
disease MESH multiple system atrophy
drug DRUGBANK Donepezil
disease MESH neurodegenerative diseases
pathway REACTOME Neurodegenerative Diseases
disease MESH Posture
pathway KEGG Parkinson disease
drug DRUGBANK Pirenzepine
disease MESH dementia
drug DRUGBANK Guanosine
disease MESH neurological disorders
drug DRUGBANK Methyl isocyanate
pathway REACTOME Reproduction

Original Article

(Visited 1 times, 1 visits today)

Leave a Comment

Your email address will not be published. Required fields are marked *